A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Enrollment status comes from the registry; check the original record for current details.
Read trial record and posted results- Registry ID
- NCT07717411
- Phase
- Phase 3
- Recruitment
- Enrolling participants
- Sponsor
- Hoffmann-La Roche
- Design
- Randomized
- Comparator
- Trontinemab; Placebo
- Planned enrollment
- 1600
- Endpoint
- Time to Progression, defined as confirmed Clinical Dementia Rating - Global Score (CDR-GS) > 0
Study ages: 55 Years to 80 Years. Other eligibility criteria apply; see the full criteria above.
Study countries and territories (including sites that may be closed): Argentina, Australia, Brazil, Canada, Chile, China, Japan, Taiwan, United Kingdom, United States.
Sites marked recruiting: Argentina, Australia, Brazil, Canada, Chile, China, Japan, Taiwan, United Kingdom, United States. Check the original registry record for locations and study-team contacts; overall recruiting status does not guarantee a local place.
Primary data collection: Jul 30, 2032 (estimated). This is not a results-release date.
No results-posting date in this record.
Evidence 1